作者
Stefan M Nidorf, Aernoud TL Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk SJ Opstal, Salem HK The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink, Donald Latchem, Pieter Hoogslag, Anastazia Jerzewski, Peter Nierop, Alan Whelan, Randall Hendriks, Henk Swart, Jeroen Schaap, Aaf FM Kuijper, Maarten WJ van Hessen, Pradyot Saklani, Isabel Tan, Angus G Thompson, Allison Morton, Chris Judkins, Willem A Bax, Maurits Dirksen, Marco Alings, Graeme J Hankey, Charley A Budgeon, Jan GP Tijssen, Jan H Cornel, Peter L Thompson
发表日期
2020/11/5
期刊
New England journal of medicine
卷号
383
期号
19
页码范围
1838-1847
出版商
Massachusetts Medical Society
简介
Background
Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited.
Methods
In a randomized, controlled, double-blind trial, we assigned patients with chronic coronary disease to receive 0.5 mg of colchicine once daily or matching placebo. The primary end point was a composite of cardiovascular death, spontaneous (nonprocedural) myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization. The key secondary end point was a composite of cardiovascular death, spontaneous myocardial infarction, or ischemic stroke.
Results
A total of 5522 patients underwent randomization; 2762 were assigned to the colchicine group and 2760 to the placebo group. The median duration of follow-up …
学术搜索中的文章
SM Nidorf, ATL Fiolet, A Mosterd, JW Eikelboom… - New England journal of medicine, 2020